Combination microdrops for ROP screening: Fewer systemic …
Jan 3, 2025 · A team of Greek researchers reported that microdrops comprised of 1.67% phenylephrine and 0.33% tropicamide were noninferior to standard drops in their efficacy and reduced the systemic adverse events caused by the standard eye drops used during retinopathy of prematurity (ROP) screening of preterm infants, 1 according to first author Aikaterini K. Seliniotaki, MD, MSc, PhD.
Discovery of a common mechanistic defect and potential therapies …
Oct 8, 2024 · A new study 1 described the underlying defect responsible for development of age-related macular degeneration (AMD) and related macular dystrophies (MDs), such as Sorsby’s fundus dystrophy, Doyne honeycomb macular dystrophy, and autosomal dominant radial drusen.. The investigators, led by Sonal Dalvi, PhD, showed that reduced activity of matrix metalloproteinase 2 (MMPs) secreted from the ...
Retinopathy associated with hair dye - modernretina.com
Dec 8, 2024 · A recent French study reported that aromatic amines in hair dye are associated with development of retinopathy, 1 according to Nicolas Chirpaz, MD, first author, from the Ophthalmology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. Chirpaz and colleagues described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...
Study suggests visual system affected in patients with mild …
Dec 8, 2024 · The results of a new study 1 suggested that the visual system is affected in patients with mild traumatic brain injury (TBI), even in patients who do not report visual disturbances, according to Marselle Rasdall, MD, from Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville. The research team reported their results in JAMA Ophthalmology.
US FDA issues Complete Response Letter for avacincaptad pegol ...
Nov 19, 2024 · Astellas Pharma Inc. announced the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for avacincaptad pegol intravitreal solution (IZERVAY).
AAO 2024: Deuterated vitamin A preserves vision in Stargardt …
Oct 20, 2024 · Christine N. Kay, MD, discussed her presentation, "Deuterated vitamin A preserves vision in Stargardt’s disease (TEASE study)" which was given at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.
AAO 2024: Suprachoroidal drug delivery in the real world
Oct 26, 2024 · Glenn C. Yiu, MD, PhD, from the University of California David, shared insights from his presentation on suprachoroidal drug delivery in the real world at this year's AAO meeting held in Chicago, Illinois.
AAO 2024: An update from Neurotech on its MacTel treatment …
Oct 18, 2024 · Thomas Aaberg, Jr, MD, Neurotech's Chief Medical Officer, shared some insights on the company's recent presentation as well as their upcoming presentations at the annual American Academy of Ophthalmology meeting being held in Chicago, Illinois.
Phototherapeutic keratectomy-assisted, customized, epi-on …
Oct 20, 2024 · Farhad Hafezi, FARVO, MD, PhD, and colleagues reported on the results achieved with phototherapeutic keratectomy (PTK)-assisted, customized, epi-on corneal crosslinking (CXL) (PACE), from the Swiss-based Elza Institute) that is a new take on CXL, in that it is not intended to just stable corneal tissue but to provide profoundly improved vision in patients with keratoconus (KCN) without ...
Ocugen will continue second phase of OCU410 ArMaDa clinical trial
Jan 3, 2025 · The Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial convened and approved continuation of the second phase of the Phase 1/2 study. The candidate being evaluated, OCU410 (AAV5-hRORA), is a novel modifier gene therapy candidate being developed for geographic atrophy (GA ...